Readnour Robin Shane's Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Nov 27, 2024
- Accession no.
- 0000950170-24-131660
- Filed
- Nov 27, 2024
- Trade date
- Nov 26-27, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $105.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Readnour Robin ShaneCIK 0001914883 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 26, 2024 | Common Stock | PPurchaseAcquired | +12,500 | $1.39 | +$17,375 | 527,288 | Indirect | |
| Nov 26, 2024 | Common Stock | PPurchaseAcquired | +12,500 | $1.39 | +$17,375 | 597,573 | Indirect | |
| Nov 27, 2024 | Common Stock | PPurchaseAcquired | +25,000 | $1.42 | +$35,500 | 552,288 | Indirect | |
| Nov 27, 2024 | Common Stock | PPurchaseAcquired | +25,000 | $1.42 | +$35,500 | 622,573 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.